17 research outputs found

    K2-136: A Binary System in the Hyades Cluster Hosting a Neptune-sized Planet

    Get PDF
    We report the discovery of a Neptune-size planet (R_p = 3.0 R⊕) in the Hyades Cluster. The host star is in a binary system, comprising a K5V star and M7/8V star with a projected separation of 40 au. The planet orbits the primary star with an orbital period of 17.3 days and a transit duration of 3 hrs. The host star is bright (V = 11.2, J = 9.1) and so may be a good target for precise radial velocity measurements. K2-136A c is the first Neptune-sized planet to be found orbiting in a binary system within an open cluster. The Hyades is the nearest star cluster to the Sun, has an age of 625–750 Myr, and forms one of the fundamental rungs in the distance ladder; understanding the planet population in such a well-studied cluster can help us understand and set constraints on the formation and evolution of planetary systems

    Reduced blood flow through intrapulmonary arteriovenous anastomoses at rest and during exercise in lowlanders during acclimatization to high altitude

    Get PDF
    Blood flow through intrapulmonary arteriovenous anastomoses (QIPAVA ) is elevated during exercise at sea level (SL) and at rest in acute normobaric hypoxia. Following high altitude (HA) acclimatization, resting QIPAVA is similar to SL, but it is unknown if this is true during exercise at HA. We reasoned that exercise at HA (5,050 m) would exacerbate QIPAVA due to heightened pulmonary arterial pressure. Using a supine cycle ergometer, seven healthy adults free from intracardiac shunts underwent an incremental exercise test at SL (25, 50, 75% of SL VO2peak ) and at HA (25, 50% of SL VO2peak ). Echocardiography was used to determine cardiac output (Q) and pulmonary artery systolic pressure (PASP) and agitated saline contrast was used to determine QIPAVA (bubble score; 0-5). The principal findings were: (1) Q was similar at SL-rest (3.9 +/- 0.47 l min-1 ) compared with HA-rest (4.5 +/- 0.49 l min-1 ; P = 0.382), but increased from rest during both SL and HA exercise (P < 0.001); (2) PASP increased from SL-rest (19.2 +/- 0.7 mmHg) to HA-rest (33.7 +/- 2.8 mmHg; P = 0.001) and, compared with SL, PASP was further elevated during HA exercise (P = 0.003); (3) QIPAVA was increased from SL-rest (0) to HA-rest (median = 1; P = 0.04) and increased from resting values during SL exercise (P < 0.05), but were unchanged during HA exercise (P = 0.91), despite significant increases in Q and PASP. Theoretical modeling of microbubble dissolution suggests that the lack of QIPAVA in response to exercise at HA is unlikely caused by saline contrast instability

    K2-136: A Binary System in the Hyades Cluster Hosting a Neptune-sized Planet

    Get PDF
    We report the discovery of a Neptune-size planet (R_p = 3.0 R⊕) in the Hyades Cluster. The host star is in a binary system, comprising a K5V star and M7/8V star with a projected separation of 40 au. The planet orbits the primary star with an orbital period of 17.3 days and a transit duration of 3 hrs. The host star is bright (V = 11.2, J = 9.1) and so may be a good target for precise radial velocity measurements. K2-136A c is the first Neptune-sized planet to be found orbiting in a binary system within an open cluster. The Hyades is the nearest star cluster to the Sun, has an age of 625–750 Myr, and forms one of the fundamental rungs in the distance ladder; understanding the planet population in such a well-studied cluster can help us understand and set constraints on the formation and evolution of planetary systems

    A TESS Dress Rehearsal: Planetary Candidates and Variables from K2 Campaign 17

    Get PDF
    We produce light curves for all ∼34,000 targets observed with K2 in Campaign 17 (C17), identifying planet candidates, eclipsing binaries, and other periodic variables. The forward-facing direction of the C17 field means follow-up can begin immediately now that the campaign has concluded and interesting targets have been identified. The C17 field has a large overlap with C6, so this latest campaign also offers an infrequent opportunity to study a large number of targets already observed in a previous K2 campaign. The timing of the C17 data release, shortly before science operations begin with the Transiting Exoplanet Survey Satellite (TESS), also lets us exercise some of the tools and methods developed for identification and dissemination of planet candidates from TESS. We find excellent agreement between these results and those identified using only K2-based tools. Among our planet candidates are several planet candidates with sizes <4 R ⊕ and orbiting stars with Kp ≲ 10 (indicating good RV targets of the sort TESS hopes to find) and a Jupiter-sized single-transit event around a star already hosting a 6 day planet candidate

    Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.

    No full text
    BACKGROUND: Supportive care interventions used to manage chemotherapy-induced myelosuppression (CIM), including granulocyte colony-stimulating factors (G-CSFs), erythropoiesis-stimulating agents (ESAs), and red blood cell (RBC) transfusions, are burdensome to patients and associated with greater costs to health care systems. We evaluated the utilization of supportive care interventions and their relationship with the myeloprotective agent, trilaciclib. METHODS: Data were pooled from three independent randomized phase 2 clinical trials of trilaciclib or placebo administered prior to chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). The impact of supportive care on the duration of severe neutropenia (DSN), occurrence of severe neutropenia (SN), and occurrence of RBC transfusions on/after week 5 was analyzed across cycles 1-4. Concordance and association between grade 3/4 anemia, RBC transfusions on/after week 5, and ESA administration was also evaluated. RESULTS: The use of G-CSFs, ESAs, or RBC transfusions on/after week 5 was significantly lower among patients receiving trilaciclib versus placebo (28.5% vs. 56.3%, p \u3c 0.0001; 3.3% vs. 11.8%, p = 0.0254; and 14.6% vs. 26.1%, p = 0.0252, respectively). Compared with placebo, trilaciclib significantly reduced DSN and SN, irrespective of G-CSF administration. RBC transfusions and ESAs were most often administered in patients with grade 3/4 anemia; however, patients typically received RBC transfusions over ESA administration. CONCLUSIONS: By improving CIM and reducing the need for associated supportive care, trilaciclib has the potential to reduce the burden of myelosuppression on patients receiving myelosuppressive chemotherapy for the treatment of ES-SCLC. TRIAL REGISTRATION: ClinicalTrials.gov (NCT02499770; NCT03041311; NCT02514447)
    corecore